Adelline Twimukye

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial

Kenneth Kintu, Thokozile R. Malaba, Jesca Nakibuka et al. · The Lancet HIV · 2020 · 117 citations · Full text

Treatment And Prevention, Dolutegravir Versus Efavirenz, Reproductive Health +11

Acceptability, perceived reliability and challenges associated with distributing <scp>HIV</scp> self‐test kits to young <scp>MSM</scp> in Uganda: a qualitative study

Stephen Okoboi, Adelline Twimukye, Oucul Lazarus et al. · Journal of the International AIDS Society · 2019 · 58 citations · Full text

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

Thokozile R. Malaba, Irene Nakatudde, Kenneth Kintu et al. · The Lancet HIV · 2022 · 50 citations · Full text

‘I fear my partner will abandon me’: the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda

Yussif Alhassan, Adelline Twimukye, Thokozile R. Malaba et al. · BMC Pregnancy and Childbirth · 2022 · 47 citations · Full text

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda

Adelline Twimukye, Miriam Laker, Eva Agnes Laker Odongpiny et al. · BMC Infectious Diseases · 2021 · 38 citations · Full text